Last reviewed · How we verify
Adipose derived mesenchymal stem cell
At a glance
| Generic name | Adipose derived mesenchymal stem cell |
|---|---|
| Also known as | Cell Therapy |
| Sponsor | Tehran University of Medical Sciences |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Procedural pain
- Headache
- Influenza like illness
- Joint swelling
- Fatigue
- Joint stiffness
- Post procedural contusion
- Nausea
- Chills
- Pyrexia
- Dizziness
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Stem Cells for Erectile Dysfunction Post RALP (PHASE1, PHASE2)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: